Rhenman & Partners Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-21,333	Closed	-$5.02M	–	94
2015 Q4	$5.02M	Buy	21,333 +1,666	+8%	+$363K	0.76%	50
2015 Q3	$3.11M	Buy	19,667 +6,534	+50%	+$1.85M	0.5%	63
2015 Q2	$4.97M	Buy	13,133 +5,200	+66%	+$2.07M	0.6%	61
2015 Q1	$3.32M	Sell	7,933 -3,734	-32%	-$1.34M	0.56%	60
2014 Q4	$3.19M	Buy	11,667 +2,467	+27%	+$613K	0.93%	38
2014 Q3	$1.79M	Sell	9,200 -4,067	-31%	-$886K	0.52%	81
2014 Q2	$3.25M	Buy	13,267 +8,354	+170%	+$1.89M	0.96%	33
2014 Q1	$1.3M	Sell	4,913 -1,087	-18%	-$416K	0.39%	76
2013 Q4	$2.18M	Buy	+6,000	New	+$2.31M	0.85%	51

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rhenman & Partners Asset Management's CLDX Position: Q1 2016 in Review

Rhenman & Partners Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 21,333 shares — an estimated $5.02M sold.

Rhenman & Partners Asset Management first reported a position in CLDX in Q4 2013 and held it in 9 quarters. The position peaked at $5.02M in Q4 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

Rhenman & Partners Asset Management reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
Rhenman & Partners Asset Management sold 21,333 Celldex Therapeutics shares in Q1 2016, an estimated $5.02M.
Rhenman & Partners Asset Management first reported a position in Celldex Therapeutics in Q4 2013 and held it in 9 quarters.
Rhenman & Partners Asset Management's Celldex Therapeutics position peaked at $5.02M in Q4 2015.
145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.